- Home
- ATRA vs ATNM Comparison
ATRA vs ATNM Comparison
Compare ATRA & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | ATNM |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9M | 42.0M |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ATRA | ATNM |
|---|---|---|
| Price | $10.51 | $1.25 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $5.00 | $4.50 |
| AVG Volume (30 Days) | ★ 3.2M | 100.6K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | 14.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,772,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $3.92 | $0.95 |
| 52 Week High | $19.15 | $1.95 |
Technical Indicators
Market Signals| Indicator | ATRA | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 55.06 |
| Support Level | $4.35 | $1.25 |
| Resistance Level | $12.91 | $1.38 |
| Average True Range (ATR) | 1.07 | 0.06 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 72.03 | 52.00 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.